Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?

·5-min read
Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?

Pioneering biotech bluebird bio (NASDAQ: BLUE) has resumed clinical trials for its blood disorder gene therapies after getting clearance from the U.S. Food and Drug Administration (FDA). The stock is up more than 10% over the past five days in response, and the FDA's move bodes well for other gene therapy companies. In February, two patients in separate studies using the company's lentiviral vector (a type of gene-therapy delivery system) came down with suspected cases of blood cancer.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting